Posters

Combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex) in retinal vein occlusion patients with cataract and macular oedema

Poster Details

First Author: M.Qureshi UK

Co Author(s):    A. Smith                    

Abstract Details

Purpose:

To evaluate the safety and efficacy of combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex) in patients with cataract and macular oedema secondary to retinal vein occlusion.

Setting:

Hereford County Hospital, Hereford, UK

Methods:

Single centre, retrospective study of nineteen eyes with macular oedema secondary to retinal vein occlusion. All eyes underwent combined phacoemulsification with IOL insertion and intravitreal dexamethasone implant 0.7mg between March 2013 and September 2017. Demographics, best-corrected visual acuity, central retinal thickness, intraocular pressure and any complications were recorded.

Results:

Fifteen eyes had central retinal vein occlusion and four eyes branch retinal vein occlusion. The mean baseline logMAR (BCVA) was 0.76 and mean baseline central retinal thickness was 307.50±122.12. Post-operatively, mean BCVA improved 0.59 (p=.040) and mean central retinal thickness improved to 282.75±92.00 (p=.045). Macular oedema returned in 14 eyes who required further treatment. No eyes had a post-operative IOP rise and one eye had post-operative vitreous haemorrhage. Five eyes(26%) had a significant rise in IOP following continued Ozurdex treatment, none of which required oral or surgical glaucoma intervention. There were no cases of retinal detachments or Endophthalmitis.

Conclusions:

Combining intravitreal dexamethasone implant with cataract surgery may be an effective approach in tackling macular oedema and improving functional outcomes in patients.

Financial Disclosure:

None